Use of novel antithrombotic agents for COVID‐19: Systematic summary of ongoing randomized controlled trials-Reference-Cited by-同舟云学术

Use of novel antithrombotic agents for COVID‐19: Systematic summary of ongoing randomized controlled trials

Published:2021-09-30 Issue:12 Volume:19 Page:3080-3089
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J. Thromb. Haemost.

Author:

Talasaz Azita H.¹²³,Sadeghipour Parham⁴^ORCID,Aghakouchakzadeh Maryam¹,Kakavand Hessam¹^ORCID,Ariannejad Hamid²,Connors Jean M.⁵^ORCID,Hunt Beverley J.⁶^ORCID,Berger Jeffrey S.⁷,Van Tassell Benjamin W.³⁸,Middeldorp Saskia⁹^ORCID,Piazza Gregory¹⁰,Weitz Jeffrey I.¹¹¹²^ORCID,Cushman Mary¹³¹⁴^ORCID,Lip Gregory Y. H.¹⁵¹⁶,Goldhaber Samuel Z.¹⁰,Bikdeli Behnood¹⁰¹⁷¹⁸^ORCID

Affiliation:

1. Department of Clinical Pharmacy Faculty of Pharmacy Tehran University of Medical Sciences Tehran Iran

2. Tehran Heart Center Tehran University of Medical Sciences Tehran Iran

3. Department of Pharmacotherapy and Outcome Science School of Pharmacy Virginia Commonwealth University Richmond Virginia USA

4. Cardiovascular Intervention Research Center Rajaie Cardiovascular Medical and Research CenterIran University of Medical Sciences Tehran Iran

5. Division of Hematology Department of Medicine Brigham and Women’s HospitalHarvard Medical School Boston Massachusetts USA

6. Haemostasis and Thrombosis Centre, St Thomas' Hospital London UK

7. Leon H. Charney Division of Cardiology Department of Medicine Center for the Prevention of Cardiovascular Disease New York University School of Medicine New York New York USA

8. Pauley Heart Center Division of Cardiology Department of Internal Medicine School of Pharmacy Virginia Commonwealth University Richmond Virginia USA

9. Department of Internal Medicine & Radboud Institute of Health Sciences (RIHS) Radboud University Medical Center Nijmegen the Netherlands

10. Cardiovascular Medicine Division Brigham and Women’s Hospital Harvard Medical School Boston Massachusetts USA

11. Department of Medicine McMaster University Hamilton Ontario Canada

12. Thrombosis and Atherosclerosis Research Institute Hamilton Ontario Canada

13. Department of Medicine University of Vermont Larner College of Medicine and University of Vermont Medical Center Burlington Vermont USA

14. Department of Pathology and Laboratory Medicine University of Vermont Larner College of Medicine and University of Vermont Medical Center Burlington Vermont USA

15. Liverpool Centre for Cardiovascular Science Liverpool Heart and Chest HospitalUniversity of Liverpool Liverpool UK

16. Department of Clinical Medicine Aalborg University Aalborg Denmark

17. Clinical Trials Center Cardiovascular Research Foundation New York New York USA

18. Center for Outcomes Research and Evaluation (CORE) Yale School of Medicine New Haven Connecticut USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.15533

Reference27 articles.

1. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up

2. Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?

3. Clinical characteristics and risk factors for symptomatic venous thromboembolism in hospitalized COVID‐19 patients: A multicenter retrospective study

4. Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19

5. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between antithrombotic therapy and mortality in patients hospitalized for COVID‑19;Thrombosis Journal;2024-01-04

2. P-Selectin de-ACTIVation in COVID-19: What Have We Learned?;Circulation;2023-08

3. Closer to FREEDOM From Uncertainty;Journal of the American College of Cardiology;2023-05

4. Thrombotic Mechanism Involving Platelet Activation, Hypercoagulability and Hypofibrinolysis in Coronavirus Disease 2019;International Journal of Molecular Sciences;2023-04-28

5. SARS‐CoV‐2 infection results in upregulation of Plasminogen Activator Inhibitor‐1 and Neuroserpin in the lungs, and an increase in fibrinolysis inhibitors associated with disease severity;eJHaem;2023-02-23